CATEGORY

Drug Development Core Lab

Field labs that focus on specific areas of assays such as ECG or sprometry.

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Drug Development Core Lab.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo
Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Drug Development Core Lab Suppliers


    Drug Development Core Lab Supplier

    Find the right-fit drug development core lab supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Drug Development Core Lab market frequently asked questions


    According to Beroe's market analysis reports, the global central laboratory services market size is expected to grow at a CAGR of 7-8 percent from 2016-2020.

    From the 2017 reports from Beroe, the global central laboratory services market was valued at around $3-3.2 billion.

    Cost efficiency, technological innovations, shift or clinical trials to emerging economies, regulatory and operational leading to increased outsourcing are the factors driving the global central lab services market.

    In the central laboratory services, there is a constant need to innovate and acquire the latest technological and medical innovations and drug development laboratory equipment acting as a market constraint. The other factor is the need for large capital investments to build and maintain a central laboratory facility.

    Covance, Quest, ICON, IQVIA, LabCorp, and PPD are the key suppliers in the global central laboratory services market.

    North America has the largest share of the global central laboratories market followed by Western Europe. However, the drug development market regions with emerging economies like China, Russia, and Southeast Asia seem to have good growth opportunities in the future.

    Pricing, specialty testing, global reach, logistics management, flexibility, proactive communication, extensive customer base, and industry reputation are some of the critical parameters which are taken into consideration to decide on a vendor.

    Some of the major reasons for the consolidation and integration of central laboratory services through acquisitions and collaborations are ' ' Expansion beyond the core services ' Catering to the growing client demands for one-stop drug development lab equipment and solutions ' Need for specialized core labs because of project-based outsourcing from pharma companies

    Centralization of specialized biomarker development is the major technological trend contributing to 30-40 percent of the technological market and having a significant impact on the central laboratory services market.

    By 2020, the market for robotics and automated liquid handling is expected to reach about $5.1 billion. It enables space optimization, provides cost efficiency, and ensures quality in central lab operations.

    Drug Development Core Lab market report transcript


    Global Market Outlook on Drug Development Core Lab

    • The market is moving toward consolidation through mergers and acquisitions. Currently, around 60-65 percent of the market share is being held by the top six service providers, where Covance and Q2 solutions are considered the leaders, contributing to 35–40 percent of the overall central lab market

    • The dynamics of outsourcing of this category by large pharma has shifted to a more consolidated base, with two or three preferred vendors to support their global central lab operations. The leading service providers include large CROs, like IQVIA, as well as specialized central laboratory service providers BARC. Acquisition of Covance by LabCorp by has allowed pharma companies to venture into new options of comprehensive outsourcing of central laboratory work

      drug-development-core-lab-global-market-size

    Outsourcing Adoption Rate

    • Currently, large pharma engages with three or more global central laboratory service providers as preferred service providers on a fee for service basis
    • This relationship is shifting to strategic partnerships (up to 10 years) with one or two full service providers (Covance, PPD) with a global in-house capacity and value or milestone- based pricing models
    • Engaging with a CRO is preferred, as they provide other related services as a value addition, when compared to a diagnostics laboratory service provider
    • Pricing, specialty testing, global reach, logistics management, flexibility, proactive communication, extensive customer base, and industry reputation are some of the critical parameters to decide on a vendor

    Market Trends–Consolidation of Core labs

    Current major trend in the Central laboratory market is the horizontal integration via consolidation and integration of services through acquisitions and collaborations.

    Major reasons for such collaborations and acquisitions:

    • To expand beyond core services
    • To meet the increasing demand of clients by providing one-stop shop solution to their clients
    • Need for specialized and experienced core labs because of project-based outsourcing from pharma companies

    Technology & Innovation Trends - Central Laboratory Services

    • Centralization of the specialized biomarker development using digital pathology results in cost and testing time reduction
    • It is the key technological trend, affecting the central laboratory services market, as it is one of the fastest growing technologies, contributing up to 30–40 percent of the technological market
    • RFID and tagging enhances the visibility and traceability of samples during the storage process
    • Adoption of dry blood spot testing technologies (CAGR 8–9 percent) resulted in process optimization as well as high cost efficiency
    • Point of Care (POC) testing is currently used for safety monitoring at a local level

    –Centralization and integration of the results locally generated would be a challenge to the central laboratory services

    –It is expected to be leveraged in the future by engaging with alliance partners at local and regional levels by the global central lab providers

    • The market for robotics & automated liquid handling (e.g., dry vapor shipping), which enables space optimization, provides cost efficiency and ensures quality in central lab operations are expected to reach about $5.1 billion by 2020

    Centralization of specialized biomarker development is the key technological trend, affecting the central laboratory services market, as it contributes to 30–40 percent of the technological market